Trials / Completed
CompletedNCT00482599
Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED)
A Multicenter, Parallel Group, Comparative Trial Evaluating the Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy and pharmacokinetics of Org 25969 in subjects with normal or impaired renal function and to evaluate the safety of Org 25969 in subjects with impaired renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sugammadex | 2 mg/kg sugammadex administered intravenously at reappearance of T2 after 0.6 mg/kg rocuronium in patients with renal impairment and control patients |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2006-04-13
- Completion
- 2006-04-13
- First posted
- 2007-06-05
- Last updated
- 2017-06-16
Source: ClinicalTrials.gov record NCT00482599. Inclusion in this directory is not an endorsement.